Switching from branded alendronate or risedronate to generic alendronate: Effect on persistence with bisphosphonate therapy in Germany

被引：0
|
作者：
Ziller, V. [1 ]
Schuessel, K.
Czeche, S.
Franzmann, A.
Kloeckner, D.
Quinzler, R.
Schulz, M. [2 ]
Moehrke, W. [3 ]
Hadji, P. [1 ]
机构：
[1] Univ Hosp Giessen & Marburg, Dept Gynecol, Marburg, Germany
[2] DAPI Verein Deutsch Arzneiprufungsinst eV, Eschborn, Germany
[3] Procter & Gamble Pharmaceut, Schwalbach A Ts, Germany
来源：
BONE | 2009年 / 44卷 / 02期
关键词：
D O I：
10.1016/j.bone.2009.03.423
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S449 / S450
页数：2
相关论文
共 50 条
  • [11] Persistence and adherence to alendronate and risedronate among chronic glucocorticoid users.
    Curtis, JR
    Westfall, AO
    Allison, JJ
    Kiefe, CI
    Saag, KG
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S279 - S279
  • [12] Treatment Discontinuation Due to Gastrointestinal Adverse Events and Decreased Bone Mineral Density in Patients Switched from Branded Alendronate to Generic Alendronate.
    Grima, D.
    Ioannidis, G.
    Papaioannou, A.
    Adachi, J. D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S210 - S210
  • [13] Comparative Safety and Effectiveness of Generic vs. Branded Alendronate in Medicare Population
    Yun, Huifeng
    Saag, Kenneth G.
    Curtis, Jeffrey R.
    Guo, Lingli
    Kilgore, Meredith
    Muntner, Paul
    Delzell, Elizabeth
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 240 - 240
  • [14] Early reduction of hip fractures demonstrates risedronate is more cost-effective than generic alendronate: The case of germany
    Kruse, H.
    Pasquale, M.
    Moehrke, W.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S164 - S164
  • [15] Early reduction of hip fractures shows risedronate is more cost-effective than generic alendronate: the case of Germany
    Kruse, H. P.
    Pasquale, M.
    Moehrke, W.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S26 - S27
  • [16] Effectiveness of bisphosphonate treatment on nonvertebral fractures: An observational cohort study of risedronate and alendronate with the addition of ibandronate
    Ringe, J. D.
    Abelson, A. G.
    Lange, J.
    Gold, D. T.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S244 - S245
  • [17] Effectiveness of bisphosphonate treatment on hip fractures: An observational cohort study of risedronate and alendronate with the addition of ibandronate
    Ringe, J. D.
    Gold, D. T.
    Lange, J.
    Abelson, A. G.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S245 - S245
  • [18] Cost-effectiveness of risedronate vs. generic alendronate: Consideration of calcium supplements
    Moehrke, W.
    Pasquale, M.
    Moeller, G.
    VALUE IN HEALTH, 2006, 9 (06) : A380 - A380
  • [19] Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
    Miller, Paul D.
    Delmas, Pierre D.
    Lindsay, Robert
    Watts, Nelson B.
    Luckey, Marjorie
    Adachi, Jonathan
    Saag, Kenneth
    Greenspan, Susan L.
    Seeman, Ego
    Boonen, Steven
    Meeves, Suzanne
    Lang, Thomas F.
    Bilezikian, John P.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10): : 3785 - 3793
  • [20] Persistence with weekly alendronate therapy among postmenopausal women
    J. C. Lo
    A. R. Pressman
    M. A. Omar
    B. Ettinger
    Osteoporosis International, 2006, 17 : 922 - 928
12345